Biohackers Gear Up for Genome Editing
By Heidi Ledford,
Nature News
| 08. 26. 2015
Untitled Document
A complete lack of formal scientific training has not kept Johan Sosa from dabbling with one of the most powerful molecular-biology tools to come along in decades.
Sosa has already used CRISPR, a three-year-old technology that makes targeted modifications to DNA, in test-tube experiments. Next week, he hopes to try the method in yeast and, later, in the model plant Arabidopsis thaliana.
Hailed for its simplicity and versatility, CRISPR allows scientists to make specific changes to a gene’s sequence more easily than ever before. Researchers have used CRISPR to edit genes in everything from bacteria to human embryos; the technique holds the potential to erase genetic defects from family pedigrees plagued by inherited disease, treat cancer in unprecedented ways or grow human organs in pigs. One researcher has even proposed modifying the elephant genome to produce a cold-adapted replica of the long-extinct woolly mammoth.
Such feats are beyond the reach of do-it-yourself (DIY) ‘biohackers’, a growing community of amateur biologists who often work in community laboratories, which typically charge a recurring fee for...
Related Articles
By Ian Sample, The Guardian | 07.04.2024
Biological models of human embryos that can develop heartbeats, spinal cords and other distinctive features will be governed by a code of practice in Britain to ensure that researchers work on them responsibly.
Made from stem cells, they mimic, to...
By Kevin Davies, Genetic Engineering & Biotechnology News | 06.27.2024
Physician-scientist Matthew Porteus, MD, PhD, has been a mainstay in the genome editing field for more than two decades. He trained at Stanford University Medical School before completing his residency and hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...